biostudies-literatureBorgna Fhorizon 2020 marie skłodowska-curie actionsnet research foundationcancer research foundation switzerlandPSI - Paul Scherrer Institute1113-1126https://www.ebi.ac.uk/biostudies/studies/S-EPMC8921065biostudies-literatureUnknown49(4)<h4>Purpose</h4>The β^¯-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with a SSTR antagonist that localizes at the cell membrane (DOTA-LM3). The aim was to identify the most favorable peptide/terbium-161 combination for the treatment of neuroendocrine neoplasms (NENs).<h4>Methods</h4>The capability of the ¹⁶¹Tb- and ¹⁷⁷Lu-labeled somatostatin (SST) analogues to reduce viability and survival of SSTR-positive AR42J tumor cells was investigated in vitro. The radiopeptides' tissue distribution profiles were assessed in tumor-bearing miEuropean journal of nuclear medicine and molecular imagingCombination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.PMC8921065701647Petersen Investigator 2018KFS-4678-02-2019-RSchibli Rvan der Meulen NPBorgna FZeevaart JRHaller SGrundler PVRodriguez JMMGinj MMuller CKoster UfalseCombination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.<h4>Purpose</h4>The β^¯-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with a SSTR antagonist that localizes at the cell membrane (DOTA-LM3). The aim was to identify the most favorable peptide/terbium-161 combination for the treatment of neuroendocrine neoplasms (NENs).<h4>Methods</h4>The capability of the ¹⁶¹Tb- and ¹⁷⁷Lu-labeled somatostatin (SST) analogues to reduce viability and survival of SSTR-positive AR42J tumor cells was investigated in vitro. The radiopeptides' tissue distribution profiles were assessed in tumor-bearing mi2022-01-01T00:00:00Z2022 Mar2025-04-04T20:50:30.796Z2024-11-13T10:34:18.813ZS-EPMC89210653462582810.1007/s00259-021-05564-0